ALPS O'Shares International Developed Quality Dividend ETF (OEFA)
Search documents
European Dividend Growth Boosts Case for This ETF
Etftrends· 2026-01-30 17:53
European Dividend Growth Boosts Case for This ETF | ETF TrendsETF Trends is now VettaFi. Read More -- Confirming the resurgence of international stocks, the widely followed MSCI EAFE Index trounced the S&P 500 last year, depressing the dividend yield on the foreign equity benchmark in the process. Rest assured equity income investors. You're not left out in the cold when it comes to international rebound.One way of getting in on that rally while accessing sturdy payouts is with the [ALPS O'Shares Internatio ...
This ETF Changes Its Spots. That May Be a Good Thing
Etftrends· 2025-10-20 13:22
Core Viewpoint - The ALPS O'Shares Europe Quality Dividend ETF has transitioned to the ALPS O'Shares International Developed Quality Dividend ETF, broadening its investment scope beyond Europe to include a wider range of developed markets outside the U.S. [1][2] Group 1: ETF Transition and Structure - The ETF now follows the O'Shares International Developed Quality Dividend Index, which is an international benchmark compared to its previous Europe-focused index [1] - OEFA has shifted from a Europe-specific fund to one that includes a broader set of developed markets, with Japan being the largest country weight at 15.65% [2] - The ETF aims to provide access to high-quality, dividend-paying large- and mid-cap companies in developed markets outside the U.S., selected based on fundamental metrics like return on assets and dividend growth [3] Group 2: Geographic Exposure and Investment Themes - Despite the change, OEFA retains significant exposure to European equities, with France, the U.K., and Switzerland accounting for approximately 40% of the fund's holdings [4] - The ETF's portfolio includes several stocks recognized by Morningstar as top international stocks, indicating potential for future growth [5][6] Group 3: Notable Holdings - Roche, a major player in the healthcare sector, is part of OEFA's portfolio, which has a 14.57% allocation to healthcare [6] - Roche's focus on biologics and innovative pipeline is highlighted as a strength, providing resilience against competition from biosimilars [7]